IMAC Holdings, Inc. BACK

Ignite Proteomics has partnered with Inova Health to conduct a biomarker study focused on late-stage cancers. This collaboration aims to enhance the understanding of cancer biomarkers, potentially leading to improved diagnostic and therapeutic strategies. The study is expected to leverage Ignite's expertise in proteomics to identify critical biomarkers that could aid in the treatment of advanced cancer patients. The collaboration may enhance product innovation and competitive positioning in the oncology market.

IMAC Holdings, Inc. has announced a research collaboration with Vanderbilt University Medical Center aimed at advancing immuno-oncology biomarker discovery. This partnership is expected to enhance the development of innovative therapies and improve patient outcomes in cancer treatment. The collaboration with a prestigious medical center could significantly impact IMAC's strategic direction and market positioning in the oncology sector.

Ignite Proteomics will present data at the NCCN Annual Conference highlighting the role of MHC-II as a predictor of response to Pembrolizumab, a key immunotherapy drug. This presentation aims to enhance understanding of patient responses to treatment, potentially impacting future therapeutic strategies in oncology. The presentation could influence key areas of product innovation and competitive positioning in the oncology market.

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), has completed the transfer of Proprietary Laboratory Analyses (PLA) code 0249U for its advanced proteomic breast cancer assay. This code, previously assigned to Theralink Technologies, is now integrated into Ignite's operations, allowing for better recognition and reimbursement of the assay, which measures functional protein activity in breast tumors. The assay is conducted in a certified laboratory and aims to improve patient outcomes by providing oncologists with data on how patients may respond to targeted therapies. The PLA code is listed at a reimbursement rate of $2,219.13, enhancing the test's adoption in clinical practice. The acquisition of a proprietary billing code significantly enhances Ignite's market position and potential for revenue growth in precision oncology.

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., published a study in the British Journal of Cancer demonstrating that measuring activated proteins in the AKT–mTOR signaling pathway is more effective than genomic profiling in predicting breast cancer therapy responses. The study found that patients with activated AKT–mTOR signaling had worse responses to standard treatments, highlighting the limitations of relying solely on genomic data. Ignite's Reverse Phase Protein Array assay offers a solution by quantifying protein activation, enabling more personalized treatment strategies. The findings support integrating proteomic analysis into clinical practice to improve patient outcomes. The study's findings could significantly enhance treatment personalization and impact IMAC Holdings' market position in precision oncology.

IMAC Holdings, Inc. has launched Ignite Proteomics, a new platform designed to enhance the matching of cancer patients with appropriate therapies. This innovative approach aims to improve treatment outcomes by utilizing advanced proteomic analysis, thereby setting a new standard in personalized cancer care. The initiative reflects IMAC's commitment to leveraging cutting-edge technology in the healthcare sector. The introduction of Ignite Proteomics is a significant strategic move that could enhance patient outcomes and strengthen IMAC's competitive position in the oncology market.

IMAC Holdings, Inc. received a deficiency notification from Nasdaq due to delayed filing of quarterly report on Form 10-Q. The delayed filing of the Form 10-Q could moderately impact the company's financial performance and compliance with Nasdaq's listing rules.

IMAC Holdings, Inc. launches subsidiary Ignite Proteomics and announces groundbreaking precision oncology case study utilizing RPPA technology. The launch of a new precision oncology assay and successful case study demonstrate significant potential for impacting patient outcomes and advancing healthcare through innovative solutions.

IMAC Holdings, Inc. appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to its Board of Directors, enhancing its research capabilities in proteomics. The addition of experienced professionals in oncology and genomics to the Board of Directors is expected to significantly impact IMAC's strategic initiatives and research capabilities.

DayDayCook appoints Jeffrey Ervin as Co-Chief Financial Officer to oversee U.S. financial operations, leveraging his capital markets experience. Jeffrey Ervin's appointment as Co-CFO is expected to have a significant impact on DayDayCook's growth strategy and investor engagement.

Faith Zaslavsky appointed as CEO of IMAC Holdings, Inc. to lead new assets in proteomics and precision medicine industry. Appointment of new CEO with extensive experience in oncology and precision medicine is a significant move that could reshape the company's trajectory and market positioning.

IMAC Holdings acquired assets of Theralink in settlement of debt default. The acquisition of Theralink's assets and termination of merger agreement could significantly impact IMAC Holdings' future strategic direction and market performance.

IMAC Holdings, Inc. (BACK) is mentioned in an article discussing three short-squeeze stocks to buy for potential 100% returns in Q2 2024. The article highlights potential significant impact on IMAC Holdings, Inc. (BACK) future and market performance through short-squeeze stock strategy.

Cingulate Inc. appoints three new directors to its board following successful capital raising activities. The appointment of experienced directors and successful fundraising activities are likely to have a significant impact on the future and market performance of IMAC Holdings, Inc.

Theralink and IMAC Holdings respond to SEC comments on Form S-4 for merger. The merger between Theralink and IMAC Holdings could significantly impact the future trajectory and market performance of IMAC Holdings.

Theralink Technologies announces promising interim results on the implementation of proteomic analysis into Inova Schar Cancer Institute's Molecular Tumor Board. The collaboration between Theralink and Inova, along with the potential impact of proteomic analysis on treatment decisions, could significantly alter IMAC Holdings, Inc.'s future trajectory and market performance.

Theralink Technologies files Form S-4 for merger with IMAC Holdings, Inc. Expected to be completed by end of Q4 2023. The merger between Theralink and IMAC Holdings is expected to create a new NASDAQ-listed company focused on end-to-end proteomics testing, which could significantly impact IMAC's future and market performance.

Tilray Brands, IMAC Holdings, and Eastman Kodak are highlighted as penny stocks with potential for high returns. The news article discusses significant investments and developments that could fundamentally alter the trajectory of IMAC Holdings, Inc. (BACK) and investor sentiment.

IMAC Holdings announced a $4.3 million private placement of convertible preferred stock and warrants. The private placement and investment into sales and marketing efforts with Theralink could significantly impact IMAC's future trajectory.

Theralink Technologies appoints Faith Zaslavsky as Chief Executive Officer. The appointment of a new CEO with extensive genomics experience and commercialization success is likely to have a significant impact on Theralink's future direction and market performance.

Theralink® signs definitive merger agreement to be acquired by IMAC Holdings, a Nasdaq listed company. The merger with Theralink Technologies has the potential to significantly impact IMAC Holdings' future market performance and strategic positioning.